San Francisco, CA – (BUSINESS WIRE) – January 26, 2023 — Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation (“Immusoft”), a clinical-stage cell therapy company dedicated to improving the lives of patients with rare or genetic diseases, announced today that the California Institute…
SEATTLE–(BUSINESS WIRE)–Immusoft, a clinical-stage cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for ISP-001 in the treatment of MPS I. The open…
Christiane Hampe, Ph.D., Senior Director of Research, will present preclinical data on Immusoft’s Immune System Programming Platform SEATTLE–(BUSINESS WIRE)–Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, today announced that it will present at the upcoming WORLDSymposium 2022 Conference,…
SAN FRANCISCO–(BUSINESS WIRE)– Immusoft of CA, a wholly owned subsidiary of Immusoft Corporation, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today that the California Institute for Regenerative Medicine (CIRM) has awarded the company a $4M grant to support the development of its ISP- 002 (for delivery of iduronate sulfatase) program in mucopolysaccharidosis type II (MPS II), an inherited disease for which patients have limited options.
Immusoft’s Immune System Programming (ISP™) technology platform has been designed to address the challenges associated with current cell therapies
Immusoft, a cell therapy company dedicated to improving the lives of patients with rare diseases, announced today the formation of its Scientific Advisory Board (SAB) composed of world-renowned experts to provide external scientific review and high-level counsel on the Company’s research and development programs.
– Two presentations to highlight the transposon-engineered B lymphocytes ISP™ platform for MPS I and enhancement of muscle mass – Seattle, Wash.–(BUSINESS WIRE) –May 12, 2020– Immusoft Corporation, a Seattle-Wash.-based, leading cell therapy company, today announced two upcoming virtual oral presentations at the ASGCT 23rd Annual…
